Brain Derived Neurotrophic Factor (BDNF) As a Predictive Biomarker of the Occurrence of Post Traumatic Stress Disorder (PTSD) | Chapter 12 | Highlights on Medicine and Medical Science Vol. 1

 Over the course of three months, the major purpose of the pilot study was to evaluate the rate of serum BDNF and the initial clinical course of a participant who had been exposed to a potentially traumatic experience. In this study, 12 participants were recruited, 7 of whom had been exposed to a traumatic event and 5 of whom had no history of psycho-trauma. There is no link between cortisol levels in the blood and BDNF levels in this investigation. The following are the study's findings: The rate of BDNF in the trauma group of volunteers was significantly lower than in the control group:

6.201.73 ng/ml in the trauma group against 21.791.76 ng/ml in the control group, indicating a p0.001 difference. When compared to those who have been through a traumatic incident, the rate of serum BDNF in victims of physical aggression is significantly lower: With a p = 0.03 difference, the assault group received 4.360.37 ng/ml while the control group received 6.941.44 ng/ml. The intensity of peritraumatic discomfort is significantly inversely linked with the amount of BDNF (r = -0.75, p0.05). The rate of serum BDNF was considerably decreased in the group with acute PTSD as compared to the group without PTSD: p = 0.001 between 7.50.9 ng/ml in the absence of PTSD (n = 4) and 4.50.4 in the presence of PTSD (n = 3).

Author (s) Details

Dr. H. Belhadj-Tahar
Mental health research group, French Association for Medical Research Advancement (AFPREMED), 9 rue du Pr Antoine Baisset, 31000 Toulouse, France.

Dr. N. Sadeg
International Medical Institute of Toxicology and Pharmacology, Bat. B8, Rue Henri Becquerel, 60230 Chambly, France.

View Book :- https://stm.bookpi.org/HMMS-V1/article/view/1185

Recent Research on Dimeric Dipeptide Mimetics of NGF and BDNF Are Promising Agents for PostStroke Therapy | Chapter 13 | Research Trends and Challenges in Medical Science Vol. 5

 

The dimeric dipeptide mimetics of the brain derived neurotrophic factor (BDNF) loops 1, 2 and 4 and
nerve growth factor (NGF) loop 4 were designed and synthesized at the Zakusov Research Institute
of Pharmacology. All of the obtained compounds activated a corresponding specific NGF or BDNF
tyrosine kinase receptor (TrkA or TrkB), but had different postreceptor signaling patterns. GSB-106
activated the ERK and AKT, whereas GSB-214 and GK-2 only activated the AKT kinase. Here we
report a comparative analysis of neuroprotective activity of these dipeptides in a model of ischemic
stroke induced by transient middle cerebral artery occlusion (MCAO). In the experiment with BDNF
mimetics, GSB-106 reduced this volume by 66% and GSB-214 by 26%. NGF mimetic GK-2 reduced
the cerebral infarct volume by 45%. Thus, BDNF mimetic, which activated both the ERK and AKT,
and NGF mimetic, which selectively activated PI3K/AKT, showed high neuroprotective efficacy. In
addition, we studied neuroprotective effects of GK-2 at the beginning of the treatment 6, 8 and 24
hours after reperfusion. The neuroprotective effect of GK-2 persisted in all these conditions. The
effectiveness of GK-2 at a delayed start of administration suggests that the dipeptide has neuroregenerative properties. The results obtained suggest a potential role for the dimeric dipeptide NGF and BDNF mimetics as therapeutic agents useful in the treatment of a stroke.

Author (s) Details

Polina Povarnina
Department of Medicinal Chemistry, Federal State Budgetary Institution “Research Zakusov Institute of Pharmacology”, Moscow, Russia.

Tatyana A. Gudasheva
Department of Medicinal Chemistry, Federal State Budgetary Institution “Research Zakusov Institute of Pharmacology”, Moscow, Russia.

Sergey B. Seredenin
Department of Pharmacogenetics, Federal State Budgetary Institution “Research Zakusov Institute of Pharmacology”, Moscow, Russia.

View Book :- https://bp.bookpi.org/index.php/bpi/catalog/book/264